(Q40958800)

English

Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease

scientific article published on 9 May 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 September 2017

Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease (English)

1 reference

Europe PubMed Central

25 September 2017

1 reference

based on heuristic

inferred from title

non-alcoholic fatty liver

1 reference

based on heuristic

inferred from title

metabolic dysfunction–associated steatotic liver disease

1 reference

based on heuristic

inferred from title

author name string

Sahar Mohamed El-Haggar

1

1 reference

Europe PubMed Central

25 September 2017

Tarek Mohamed Mostafa

2

1 reference

Europe PubMed Central

25 September 2017

publication date

9 May 2015

1 reference

Europe PubMed Central

25 September 2017

Hepatology international

1 reference

Europe PubMed Central

25 September 2017

9

1 reference

Europe PubMed Central

25 September 2017

3

1 reference

Europe PubMed Central

25 September 2017

471-479

1 reference

Europe PubMed Central

25 September 2017

https://scigraph.springernature.com/pub.10.1007/s12072-015-9633-1

0 references

Nonalcoholic fatty liver disease and cardiovascular risk

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Nonalcoholic fatty liver disease: an agenda for clinical research

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Clinical features and natural history of nonalcoholic steatosis syndromes

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Role of inflammation in nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Roles of PPARs in NAFLD: potential therapeutic targets

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH).

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

The utility of radiological imaging in nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Mechanism of action of fibrates on lipid and lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Cytokines in alcoholic liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

A pilot trial of pentoxifylline in nonalcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Cytokines in alcoholic and nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence.

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia.

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Combination therapy with metformin and fenofibrate for insulin resistance in obesity.

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

TGF-ß in wound healing: a review

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Apoptosis and cytokines in non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign?

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Role of cytokines in the pathogenesis of non-alcoholic Fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

TGF-β signal shifting between tumor suppression and fibro-carcinogenesis in human chronic liver diseases

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Hyaluronan: its nature, distribution, functions and turnover

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, improves hepatic microcirculatory patency and oxygen availability in a high-fat-diet-induced fatty liver in mice

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Practice and complications of liver biopsy. Results of a nationwide survey in Switzerland

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Pentoxifylline prevents pig serum-induced rat liver fibrosis by inhibiting interleukin-6 production

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg-negative chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9633-1

21 January 2018

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25956613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of pentoxifylline on TNF-alpha production by peripheral blood mononuclear cells in patients with nonalcoholic steatohepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25956613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence of and risk factors for hepatic steatosis in Northern Italy

1 reference

https://pubmed.ncbi.nlm.nih.gov/25956613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects of diet-induced obesity on hepatocyte insulin signaling pathways and induction of non-alcoholic liver damage

1 reference

https://pubmed.ncbi.nlm.nih.gov/25956613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25956613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of pentoxifylline in rat and swine models of hepatic fibrosis: role of fibroproliferation in its mechanism

1 reference

https://pubmed.ncbi.nlm.nih.gov/25956613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of pentoxifylline on the fibrogenic functions of cultured rat liver fat-storing cells and myofibroblasts

1 reference

https://pubmed.ncbi.nlm.nih.gov/25956613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Anti-fibrosis effects of fenofibrate in mice with hepatic fibrosis].

1 reference

https://pubmed.ncbi.nlm.nih.gov/25956613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver

1 reference

https://pubmed.ncbi.nlm.nih.gov/25956613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of pentoxifylline pretreatment on Kupffer cells in rat liver transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/25956613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25956613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25956613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/25956613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblast-like cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/25956613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/25956613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pentoxifylline maintains hepatocellular function and improves cardiac performance during early sepsis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25956613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel morphologic findings in alcoholic liver disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25956613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline

1 reference

https://pubmed.ncbi.nlm.nih.gov/25956613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vasodilator action of pentoxifylline on microcirculation of rat cremaster muscle

1 reference

https://pubmed.ncbi.nlm.nih.gov/25956613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Non-alcoholic fatty liver disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25956613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pentoxifylline blocks hepatic stellate cell activation independently of phosphodiesterase inhibitory activity.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25956613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25956613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12072-015-9633-1

1 reference

Europe PubMed Central

25 September 2017

1 reference

Europe PubMed Central

25 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40958800&oldid=1911222911"